Bretylium Tosylate; adverse effects in acute myocardial infarction.
The effects of bretylium tosylate in managing acute myocardial infarction were studied in 16 patients within 24 hours from the onset of symptoms and were compared to those of lidocaine in a comparable group of 15 patients. Both drugs were equally effective in preventing cardiac arrhythmias during the 48 hours of trial. No deleterious hemodynamic effects were associated with lidocaine treatment. However, marked supine hypotension developed in seven patients treated with bretylium. No changes occurred simultaneously in heart rate, left ventricular ejection time, or central venous pressure. The occurrence of hypotension correlated with a poor initial hemodynamic state. The substantial and unpredictable circulatory effects of bretylium in acute myocardial infarction contraindicates its routine use in the prevention of infarction arrhythmias.
D001145:Arrhythmias, Cardiac / Q000517:prevention & control; D001794:Blood Pressure; D001949:Bretylium Compounds / Q000009:adverse effects*; D002302:Cardiac Output; D002496:Central Venous Pressure; D006339:Heart Rate; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D008012:Lidocaine / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy*
D001949:Bretylium Compounds; D008012:Lidocaine